Report
Eric Le Berrigaud ...
  • Jean-Jacques Le Fur

SANOFI: AdCom’s experts split votes over Zynquista | BUY - Top Picks | EUR94(

SANOFI - BUY - Top Picks | EUR94(+29%)
AdCom’s experts split votes over Zynquista

Splithood AdCom in Type 1 diabetes
Peak sales could reach EUR600m in type 1 diabetes
Development in progress in type 2 diabetes
Buy rating reiterated
Underlying
Sanofi

Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Eric Le Berrigaud

Jean-Jacques Le Fur

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch